About Biomimiq
Biomimiq is a company based in Leiden (Netherlands) founded in 2010. The company has 43 employees as of April 05, 2024. Biomimiq offers products and services including In Vitro Human Skin Equivalents (HSEs). Biomimiq operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Leiden, Netherlands
- Employees 43 as on 05 Apr, 2024
-
Sectors
HealthcareChemicals & Materials
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$10.67 M (USD)-50.13as on Mar 31, 2023
-
Net Profit
$190.06 K (USD)-46.98as on Mar 31, 2023
-
EBITDA
$276 K (USD)-44.38as on Mar 31, 2023
-
Latest Funding Round
Not available
- Investors
-
Employee Count
43
as on Apr 05, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biomimiq
Biomimiq offers a comprehensive portfolio of products and services, including In Vitro Human Skin Equivalents (HSEs).
Customizable models for skin compound testing and research purposes.
Funding Insights of Biomimiq
Investors in Biomimiq
Biomimiq has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include LifeSciences@Work.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
LifeSciences@Work is recognized as a national accelerator for life sciences startups.
|
Locked | Locked | Locked |
Investor details for Biomimiq
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biomimiq
Investment portfolio details for Biomimiq
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biomimiq
Detailed financials for Biomimiq
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biomimiq Comparisons
Peer comparison for Biomimiq
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biomimiq
Biomimiq operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Biomimiq
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biomimiq
Complete news archive for Biomimiq
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biomimiq
Biomimiq was founded in 2010.
Biomimiq is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
As of Apr 05, 2024, the latest employee count at Biomimiq is 43.
Annual revenue of Biomimiq is $10.67M as on Mar 31, 2023.
Biomimiq is a biotechnology startup spun-off from the Leiden University Medical Center that services centered around in vitro models of the human skin mimicking both healthy as well as diseased states. The company was formed the exclusive licensing agreement between Leiden University Medical Center and Aeon Astron Europe B.V. and is thus part of the Aeon Astron group. Biomimiqs services are based on what the company refers to as in vitro human skin equivalents or HSEs. The company has developed healthy Leiden epidermal skin model (LEM), healthy full-thickness fibroblast-derived matrix (FDM), healthy full thickness model (FTM), which enable a wide range of in vitro assays. Biomimiq has also developed a range of diseased skin models including skin wound models, skin aging models, and skin infection models to enable screening and MoA studies on drug candidates.
Biomimiq's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biomimiq offers In Vitro Human Skin Equivalents (HSEs).
Biomimiq has 1 investor. Key investors include LifeSciences@Work.